< Back to companies

Rea developed the first at-home diagnostic test that tracks biochemical markers of preterm birth (PTB). Our solution allows doctors to continuously follow up pregnant women at risk of PTB to anticipate a potential early delivery. Today, all of the medical examinations to monitor the risk of a PTB require invasive inspections of pregnant women. These tests have to be performed by a medical professional in a hospital, limiting significantly the number of pregnant women that can be tested. Our technology could enable obstetricians to provide personalized prophylactic treatments to decrease neonatal mortalities and morbidities.

Only accessible to MedStartr community members. Join now

Company Info

Founded
2022
Website
readiagnostics.com/

Categories

Maternal HealthDiagnosticsScreening & Early DetectionRemote Monitoring
Only accessible to MedStartr community members. Join now

What do you think of Rea Diagnostics?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now